Lack of Association Between 5α-Reductase Inhibitors and Depression.

  title={Lack of Association Between 5$\alpha$-Reductase Inhibitors and Depression.},
  author={Tess E Dyson and Matthew A. Cantrell and Brian C Lund},
  journal={Journal of Urology},
PURPOSE Depressed mood and suicidality reported with 5α-reductase inhibitors (5-ARIs; finasteride and dutasteride) during post-marketing surveillance resulted in the addition of depression risk to finasteride labeling. As peer-reviewed studies are limited and have reported mixed findings, we aimed to further evaluate 5-ARI exposure and depression risk using sequence symmetry analysis. MATERIALS AND METHODS National Veterans Health Administration administrative data were used to identify 53… 

Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea

The risk of depression associated with 5ARI was not meaningfully different from AB in Korea, which suggests that medical officials should provide the most appropriate medication for BPH patients by considering both treatment benefits and depression risk.

Montelukast and neuropsychiatric events – a sequence symmetry analysis

Initiation of montelukast was not associated with increased risk of a variety of NEs in this sequence symmetry analysis involving adult patients in the VHA, and the hypothesis that NEs are associated with montelUKast initiation is not supported.

Association between Significant Depressive Symptoms and Prostatic Symptoms among Patients with Benign Prostatic Hyperplasia

A higher proportion of participants had significant depressive symptoms, the risk of which is increased by both clinical and socio-demographic variables.

Prescribing cascades in community‐dwelling adults: A systematic review

Prescribing cascades occur for a broad range of medications and should be included in the differential diagnosis for patients presenting with new symptoms, particularly older adults and those who started a new medication in the preceding 12 months.

Pharmacological Management of Pattern Hair Loss

  • S. SatturI. Sattur
  • Medicine
    Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India
  • 2021
This article attempts to review the literature on incorporating pharmacologic treatments along with hair transplantation in their management of pattern hair loss, and the authors add to this, with their experience of over two decades.

Further Studies of Effects of Finasteride on Mood and Suicidal Risk.



Association of Suicidality and Depression With 5&agr;-Reductase Inhibitors

In a large cohort of men ages 66 years or older, an increased risk of suicide associated with 5&agr;-reductase inhibitor use was not demonstrated, however, the risk of self-harm and depression were increased compared with unexposed men.

Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

Overall risk of depression after 5-ARI was significantly not high, however its clinical importance needs validation by further studies, which could provide useful information for both clinicians and patients.

Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

A literature search reviewing adverse events of 5-alpha reductase inhibitors as they relate to prostate cancer, psychological effects, sexual health, and use in women found they were well-tolerated in both men and women, but not without risk.

Risk of Incident Antidepressant‐Treated Depression Associated with Use of 5α‐Reductase Inhibitors Compared with Use of α‐Blockers in Men with Benign Prostatic Hyperplasia: A Population‐Based Study Using the Clinical Practice Research Datalink

To estimate the risk of incident antidepressant‐treated depression in men with benign prostatic hyperplasia (BPH) who were prescribed 5α‐reductase inhibitors (5‐ARIs) compared with those prescribed

Evidence of Depression Provoked by Cardiovascular Medication: A Prescription Sequence Symmetry Analysis

  • J. Hallas
  • Medicine, Psychology
  • 1996
A new approach to such analyses that effectively controls for confounders that are stable over time is presented, and prescription sequence symmetry analysis may be useful as a screening tool.

Depressive symptoms in patients diagnosed with benign prostatic hyperplasia

Prevalence of depressive symptoms in patients diagnosed with BPH is associated with severity of LUTS, erectile dysfunction, nocturia, BPH pharmacotherapy (5αRIs), sedentary life style, and comorbidities including obesity.

Drug or symptom‐induced depression in men treated with alpha1‐blockers for benign prostatic hyperplasia? A nested case–control study

The aim was to assess the risk of depression with α1‐blockers independently of that associated with symptoms being treated and concurrent illness.

Update on AUA guideline on the management of benign prostatic hyperplasia.

Urologic diseases in America project: benign prostatic hyperplasia.

While the number of outpatient visits for BPH increased consistently during the 1990s, there was a dramatic decrease in the use of transurethral prostatectomy, inpatient hospitalization and length of hospital stay for this condition in 2000.